Cogent Biosciences, Inc. COGT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Cogent Biosciences, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s return on equity?
- Cogent Biosciences, Inc. (COGT) reported return on equity of -85.7% in Q1 2026.
- How has Cogent Biosciences, Inc.'s return on equity changed year-over-year?
- Cogent Biosciences, Inc.'s return on equity decreased by 2.0% year-over-year, from -84% to -85.7%.
- What is the long-term trend for Cogent Biosciences, Inc.'s return on equity?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s return on equity has grown at a 5.6% compound annual growth rate (CAGR), from -56.2% to -73.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.